Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fibroblast growth factor 6 in medicine for relieving non-alcoholic steatohepatitis liver injury

A steatohepatitis, non-alcoholic technology, applied in the field of medicine and biology, to achieve the effect of reducing expression

Active Publication Date: 2020-09-29
SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no report on the relationship between FGF6 and NASH.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fibroblast growth factor 6 in medicine for relieving non-alcoholic steatohepatitis liver injury
  • Application of fibroblast growth factor 6 in medicine for relieving non-alcoholic steatohepatitis liver injury
  • Application of fibroblast growth factor 6 in medicine for relieving non-alcoholic steatohepatitis liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] 1. Construct a high-fat diet (Highfatdiet, HFD)-induced non-alcoholic steatohepatitis (NASH) mouse model (abbreviation: NASH mouse model): refer to relevant literature (ImajoK, FujitaK, YonedaM, et al. mediatedsignaling.CellMetab.2012;16(1):44-54), C57BL / 6J mice were stimulated with low-dose LPS after long-term high-fat diet to simulate NASH-related liver injury. Mice were purchased from Shanghai Slack Experimental Animal Co., Ltd.

[0032] Specifically, 20 healthy male 8-week-old C57BL6 mice were selected, given a 12-week long-term high-fat diet, and then given intraperitoneal injection of LPS (0.25 mg / kg), once a day, for 4 weeks to establish a NASH mouse model. Two weeks after LPS injection, NASH mice were established. LPS was purchased from Sigma-aldrich, USA, item number: L2630-100MG.

[0033] The mRNA sequence of the mouse FGF6 gene: bases 1-44 are the 5'-untranslated region, bases 45-671 are the amino acid coding region; bases 672-1232 are the 3'-untranslated r...

experiment example 1

[0038] Experimental Example 1: Therapeutic effect of FGF6 within the effective dose range on a mouse model of non-alcoholic steatohepatitis induced by a high-fat diet.

[0039] 1. Experimental method:

[0040] (1) Select 20 healthy male 8-week-old C57BL6 mice, and randomly divide them into two groups, 10 mice in each group, and give them intraperitoneal injection of PBS reagent (control solvent) or FGF6 injection (1 mg / kg), once a day (morning 10 o'clock injection).

[0041] (2) 20 NASH mice were selected and randomly divided into two groups, 10 in each group, and were given intraperitoneal injection of PBS reagent (control solvent) or FGF6 injection (1 mg / kg), once a day (injection at 10 am).

[0042] The details of animal grouping and drug administration are shown in Table 1:

[0043] Table 1: Animal grouping and drug administration

[0044] group Number of animals (only) dose Dosing cycle (days) Healthy PBS Group 10 Same volume of control solvent ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of a fibroblast growth factor. The fibroblast growth factor is a fibroblast growth factor 6, and the application is an application in a medicine for relieving non-alcoholic steatohepatitis liver injury. The application has the following advantages: after acting, the fibroblast growth factor 6 has no obvious toxic effect, and can effectively relieve the NASHliver injury; inflammatory cell aggregation and collagen fiber deposition can be effectively relieved; macrophage activation can be effectively inhibited; and the expression of inflammatory factors inthe liver can be effectively reduced.

Description

technical field [0001] The invention relates to the field of medicine and biology, in particular to the application of fibroblast growth factor 6 in medicine for alleviating liver damage caused by non-alcoholic steatohepatitis. Background technique [0002] With the improvement of living standards and changes in lifestyle, the prevalence of non-alcoholic fatty liver disease (Non-alcoholic Fatty Liver disease, NAFLD) is increasing year by year, and has become the most important non-infectious liver disease in the world. Globally, the prevalence of NAFLD is approximately 25%, being highest in the Middle East and South America and lowest in Africa. In the United States, the number of NAFLD cases is projected to increase from 83.1 million (25% of the population) in 2015 to 100.9 million in 2030. In North America and Europe, NAFLD is often associated with central obesity (approximately 83%), whereas in Asia, a significant proportion of "lean NASH" patients occurs despite a norma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/18A61P1/16
CPCA61K38/1825A61P1/16
Inventor 万健
Owner SHANGHAI PUDONG NEW AREA PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com